Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
- PMID: 18184433
- PMCID: PMC2211476
- DOI: 10.1186/1742-2094-5-2
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
Abstract
Substantial basic science and clinical evidence suggests that excess tumor necrosis factor-alpha (TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. In addition to its pro-inflammatory functions, TNF-alpha has recently been recognized to be a gliotransmitter that regulates synaptic function in neural networks. TNF-alpha has also recently been shown to mediate the disruption in synaptic memory mechanisms, which is caused by beta-amyloid and beta-amyloid oligomers. The efficacy of etanercept, a biologic antagonist of TNF-alpha, delivered by perispinal administration, for treatment of Alzheimer's disease over a period of six months has been previously reported in a pilot study. This report details rapid cognitive improvement, beginning within minutes, using this same anti-TNF treatment modality, in a patient with late-onset Alzheimer's disease. Rapid cognitive improvement following perispinal etanercept may be related to amelioration of the effects of excess TNF-alpha on synaptic mechanisms in Alzheimer's disease and provides a promising area for additional investigation and therapeutic intervention.
Figures

Comment in
-
Perispinal etanercept: potential as an Alzheimer therapeutic.J Neuroinflammation. 2008 Jan 10;5:3. doi: 10.1186/1742-2094-5-3. J Neuroinflammation. 2008. PMID: 18186919 Free PMC article.
Similar articles
-
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.BMC Neurol. 2008 Jul 21;8:27. doi: 10.1186/1471-2377-8-27. BMC Neurol. 2008. PMID: 18644112 Free PMC article. Clinical Trial.
-
Perispinal etanercept for treatment of Alzheimer's disease.Curr Alzheimer Res. 2007 Dec;4(5):550-2. doi: 10.2174/156720507783018217. Curr Alzheimer Res. 2007. PMID: 18220520 Review.
-
Perispinal etanercept for neuroinflammatory disorders.Drug Discov Today. 2009 Feb;14(3-4):168-77. doi: 10.1016/j.drudis.2008.10.005. Epub 2008 Dec 6. Drug Discov Today. 2009. PMID: 19027875 Review.
-
Perispinal etanercept: potential as an Alzheimer therapeutic.J Neuroinflammation. 2008 Jan 10;5:3. doi: 10.1186/1742-2094-5-3. J Neuroinflammation. 2008. PMID: 18186919 Free PMC article.
-
Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease.Curr Alzheimer Res. 2012 Jan;9(1):99-109. doi: 10.2174/156720512799015073. Curr Alzheimer Res. 2012. PMID: 22191562 Review.
Cited by
-
Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs.Clin Rheumatol. 2021 Apr;40(4):1221-1231. doi: 10.1007/s10067-020-05372-1. Epub 2020 Aug 30. Clin Rheumatol. 2021. PMID: 32862311 Review.
-
The core inflammatory factors in patients with major depressive disorder: a network analysis.Front Psychiatry. 2023 Aug 25;14:1216583. doi: 10.3389/fpsyt.2023.1216583. eCollection 2023. Front Psychiatry. 2023. PMID: 37692303 Free PMC article.
-
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease.J Inflamm Res. 2008;1:29-39. doi: 10.2147/jir.s4397. Epub 2008 Nov 6. J Inflamm Res. 2008. PMID: 22096345 Free PMC article.
-
Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge.Neuropsychopharmacology. 2015 Jan;40(2):502-12. doi: 10.1038/npp.2014.199. Epub 2014 Aug 8. Neuropsychopharmacology. 2015. PMID: 25103178 Free PMC article.
-
Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.CNS Drugs. 2012 Dec;26(12):1051-70. doi: 10.1007/s40263-012-0013-2. CNS Drugs. 2012. PMID: 23100196 Clinical Trial.
References
-
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421. doi: 10.1016/S0197-4580(00)00124-X. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical